Trial Profile
Phase I/II Study Using Imatinib and s.c. BL-8040 (Novel Anti CXCR4 Antagonist) for Improving Molecular Response in Chronic Myelogenous Leukemia (CML) Patients in First Chronic Phase Achieving Less Than Optimal Response With Imatinib
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Motixafortide (Primary) ; Imatinib
- Indications Chronic myeloid leukaemia
- Focus Adverse reactions
- 11 Aug 2016 Status changed from not yet recruiting to withdrawn prior to enrolment due to loss of support
- 17 Sep 2014 Planned initiation date changed from 1 May 2014 to 1 Dec 2014, as reported in a BioLineRx media release.
- 06 Aug 2014 According to a BioLineRx media release, this trial is expected by the end of 2014.